Recombinant Human Midkine

Home/Recombinant Proteins/Recombinant Human Midkine

Pricing & Details

Product. No.M132
Alternate Names
MK, FLJ27379, NEGF2 (Neurite Growth-Promoting Factor 2)
Expression Host
E. coli
Species
Human
Prod No.
Size
Price
Avail.
Qty
Add to cart
M132-10 µg
10 µg
$309.00
In stock
Max:
Min: 1
Step: 1
M132-50 µg
50 µg
$409.00
In stock
Max:
Min: 1
Step: 1

Background

Midkine (MK), also known as MDK and NEGF2, is a non-glycosylated, highly-basic heparin-binding growth factor and member of the NEGF family. Midkine is functionally-related to pleiotrophin and appears to act through a variety of receptors, dependent on the biological activities elicited in target cells. PTP-zeta, LRP, ALK and syndecans are considered to be its primary receptors (1). Midkine is composed of two disulfide-linked domains where the C-terminally located domain contains two heparin binding sites and is usually responsible for midkine activity, though part of the MK activity is enhanced by dimerization. It is a developmentally important retinoic acid-responsive gene product strongly induced during mid-gestation, hence the name midkine. Restricted mainly to certain tissues in the normal adult, MK is strongly induced during oncogenesis, inflammation and tissue repair (2). It is also capable of exerting activities such as cell proliferation, cell migration, angiogenesis and fibrinolysis. In addition to normal development, MK is also involved in the pathogenesis of inflammatory diseases and human carcinomas such as esophageal, stomach, colon, pancreatic, thyroid, lung, urinary, hepatocellular, neuroblastoma, glioblastoma and Wilm´s tumor (3). High MK levels are associated with poor prognosis in some types of cancer. The increased expression in many carcinomas indicates that MK can be applied to the diagnosis of malignancy. MK is also expressed during the reparative stage of bone fractures and suppresses infection of certain viruses, including HIV in target cells (4). MK application could be a promising therapeutic strategy for the treatment of ischemic heart failure (5).

Protein Details

Purity
>97% by SDS-PAGE and analyzed by silver stain.
Endotoxin Level
<0.01EU/µg as determined by the LAL method
Biological Activity
The biological activity of Human MDK was determined by its ability to enhance neurite growth of cerebral cortical neurons of E10 chick embryos (Muramatsu, H. and Muramatsu, T., 1991, Biochem. Biophys. Res. Commu. 177:652). Optimal neurite outgrowth was observed when neurons were plated on 96-well culture plates that had been pre-coated with 100 ml/well of a solution of 3.0 - 8.0 mg/ml of rhMK.
Expression Host
E. coli
Protein Accession No.
Amino Acid Sequence
kkkdkvkk ggpgsecaew awgpctpssk dcgvgfregt cgaqtqrirc rvpcnwkkef gadckykfen wgacdggtgt kvrqgtlkka rynaqcqeti rvtkpctpkt kakakakkgk gkd
N-terminal Sequence Analysis
Lys23
State of Matter
Lyophilized
Predicted Molecular Mass
The predicted molecular weight of Recombinant Human MDK is Mr 13.3 kDa.
Formulation
This recombinant protein was 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 with no calcium, magnesium, or preservatives.
Storage and Stability
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Country of Origin
USA
Shipping
Next Day Ambient
PubMed
NCBI Gene Bank

References & Citations

1. Takashi, M. et al. (2002) J. Biochem. (Tokyo) 132:359
2. Muramatsu, H. et al. (1991) Biochem. Biophy. Res. Comm. 177:652
3. Kato, M. et al. (2000) Mod. Pathol. 13:1060
4. Ohta, S. et al. (1999) J. Bone Miner. Res. 14:1132
5. Kenji, K. et al. (2003) Am. J. Physiol. Heart Circ. Physiol. 296:462
IMPORTANT Use lot specific datasheet for all technical information pertaining to this recombinant protein.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok